SCA
BIIB icon

Salient Capital Advisors’s Biogen BIIB Stock Holding History

Salient Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,110
Closed -$850K – 215
2017
Q1 		$850K Buy
3,110
+500
+19% +$141K 0.02% 141
2016
Q4 		$740K Buy
2,610
+50
+2% +$14.8K 0.01% 145
2016
Q3 		$801K Buy
2,560
+200
+8% +$59.2K 0.02% 128
2016
Q2 		$571K Buy
2,360
+400
+20% +$105K 0.01% 160
2016
Q1 		$510K Buy
1,960
+400
+26% +$106K 0.01% 169
2015
Q4 		$478K Buy
1,560
+536
+52% +$154K 0.01% 181
2015
Q3 		$299K Buy
+1,024
New +$338K 0.01% 199

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Salient Capital Advisors's BIIB Position: Q2 2017 in Review

Salient Capital Advisors sold out of Biogen (BIIB) in Q2 2017, closing a stake of 3,110 shares — an estimated $850K sold.

Salient Capital Advisors first reported a position in BIIB in Q3 2015 and held it in 7 quarters. The position peaked at $850K in Q1 2017. 993 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Salient Capital Advisors reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 3,110 Biogen shares in Q2 2017, an estimated $850K.
  • Salient Capital Advisors first reported a position in Biogen in Q3 2015 and held it in 7 quarters.
  • Salient Capital Advisors's Biogen position peaked at $850K in Q1 2017.
  • 993 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Salient Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.